Healthcare Industry News: Integrated BioPharma
News Release - August 9, 2007
Newly Created Hemosol BioPharma Inc. on the Hunt for Partnership, Licensing and Acquisition TargetsTORONTO, Aug. 9 (Healthcare Sales & Marketing Network) - Hemosol BioPharma Inc. (Hemosol) announced today that it is actively seeking partnerships, licensing arrangements and acquisitions of products or companies to supplement its own development programs and commercialization plans. Products of interest include therapeutic proteins derived from blood plasma or other sources, including bioprocess streams, as well as other sterile injectable biopharmaceuticals.
Hemosol BioPharma Inc. was formed July 6, 2007 following the acquisition of substantially all the assets of Hemosol Corp., a well-known Canadian biopharmaceutical company, by Catalyst Fund Limited Partnership II, a billion dollar private equity fund based in Toronto and managed by The Catalyst Capital Group Inc. Hemosol's unique assets include a commercial scale cGMP manufacturing facility located in Mississauga and a substantial portfolio of intellectual property supporting a pipeline of new products. Key staff have been retained to execute on the business plan and operations. Hemosol intends to continue the development of therapeutic plasma proteins, as well as its own product pipeline. The company plans to build upon current business relationships and development activities through the licensing and acquisition of complementary products with near-term revenue potential.
"Through this strategic partnership, licensing and acquisition program, we will create a revenue generating company that will be a significant player in North American biotechnology," stated Dr. David Bell, V.P. of Drug Development.
Dr. Dirk Alkema, V.P. of Operations, notes that, "Hemosol is in a position to leverage its cGMP facility and know how in the manufacture and testing of biopharmaceutical products to offer services to prospective clients, to generate revenue and accelerate the company's growth."
Newton Glassman, Managing Partner of Catalyst remarked: "The Catalyst Capital Group Inc. is extremely pleased to add Hemosol BioPharma Inc. to our portfolio of companies. We are confident that with the solid financial backing and strategic support provided by Catalyst, Hemosol is in a good position to make strategic acquisitions and partnerships and to continue to develop its plasma business and diverse pipeline of products." About Hemosol BioPharma Inc.
About Hemosol BioPharma Inc.
Hemosol BioPharma Inc. is an Integrated BioPharmaceutical developer and manufacturer of biologics, particularly blood-related protein based therapeutics. The company is pursuing a strategy to manufacture and market therapeutic products in North America under its own label or in partnership with others. Hemosol possesses a strong understanding of the market and business opportunities for therapeutic proteins and experience in the development and manufacture of biological products. Hemosol's extensive pipeline of products address unmet medical needs in major medical markets. Such products include protein-based therapeutics to treat infectious disease, cancer and anemia.
About The Catalyst Capital Group Inc.
The Catalyst Capital Group Inc. is an investment management company that manages over $1 Billion on behalf of two private equity funds.
Statements in this release that are not strictly historical are forward-looking statements and include statements about business, strategic and development plans and objectives. These forward-looking statements involve expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements.
Source: Hemosol BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.